rs10455872
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (A;A) | 0 | common/normal |
| (A;G) | 2 | 1,51x increased Coronary Heart disease risk |
| (G;G) | 3 | 2,57x increased Coronary Heart disease risk |
| Reference | GRCh38 38.1/141 |
| Chromosome | 6 |
| Position | 160589086 |
| Gene | LPA |
| is a | snp |
| is | mentioned by |
| dbSNP | rs10455872 |
| dbSNP (classic) | rs10455872 |
| ClinGen | rs10455872 |
| ebi | rs10455872 |
| HLI | rs10455872 |
| Exac | rs10455872 |
| Gnomad | rs10455872 |
| Varsome | rs10455872 |
| LitVar | rs10455872 |
| Map | rs10455872 |
| PheGenI | rs10455872 |
| Biobank | rs10455872 |
| 1000 genomes | rs10455872 |
| hgdp | rs10455872 |
| ensembl | rs10455872 |
| geneview | rs10455872 |
| scholar | rs10455872 |
| rs10455872 | |
| pharmgkb | rs10455872 |
| gwascentral | rs10455872 |
| openSNP | rs10455872 |
| 23andMe | rs10455872 |
| SNPshot | rs10455872 |
| SNPdbe | rs10455872 |
| MSV3d | rs10455872 |
| GWAS Ctlg | rs10455872 |
| GMAF | 0.03122 |
| Max Magnitude | 3 |
| ? | (A;A) (A;G) (G;G) | 28 |
|---|---|---|
|
| ||
[PMID 20032323] Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease rs10455872, was associated with about 1.5-fold increased risk of Coronary Heart Disease. celera
[PMID 20160194] Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians
[PMID 20605575] Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus
[PMID 21900290
] Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes
[PMID 22368281] Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: Importance of Lp(a).
| GWAS snp | |
|---|---|
| PMID | [PMID 22331829] |
| Trait | |
| Title | Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. |
| Risk Allele | |
| P-val | 5E-15 |
| Odds Ratio | 6.8000 None |
[PMID 21127300] Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk.
[PMID 21252144] Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
[PMID 21283670] Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans.
[PMID 21305047] Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey.
[PMID 22560621] Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
| GWAS snp | |
|---|---|
| PMID | [PMID 23118302] |
| Trait | Lipoprotein-associated phospholipase A2 activity change in response to statin therapy |
| Title | Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy. |
| Risk Allele | G |
| P-val | 2E-16 |
| Odds Ratio | 4.80 [0.82-2.78] percent increase |
[PMID 23735648] Validation and Quantification of Genetic Determinants of Lipoprotein-a Levels and Predictive Value for Angiographic Coronary Artery Disease
[PMID 23978127] Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention
[PMID 24161338] Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
| GWAS snp | |
|---|---|
| PMID | [PMID 23388002]
|
| Trait | Aortic-valve calcification |
| Title | Genetic associations with valvular calcification and aortic stenosis. |
| Risk Allele | G |
| P-val | 3E-11 |
| Odds Ratio | 2.05 [1.66-2.53] |
[PMID 24622370] Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
[PMID 22898070] Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism.
[PMID 23100282] Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
[PMID 23278389] Two rare variants explain association with acute myocardial infarction in an extended genomic region including the apolipoprotein(A) gene.
[PMID 23375930] Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.
[PMID 24776095] LPA rs10455872 polymorphism is associated with coronary lesions in Brazilian patients submitted to coronary angiography
[PMID 24903972] Genetic predisposition to calcific aortic stenosis and mitral annular calcification
| GWAS snp | |
|---|---|
| PMID | [PMID 24262325]
|
| Trait | Coronary artery disease or ischemic stroke |
| Title | Shared genetic susceptibility to ischemic stroke and coronary artery disease: a genome-wide analysis of common variants. |
| Risk Allele | |
| P-val | 2E-12 |
| Odds Ratio | NR NR |
[PMID 24760552] Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts
[PMID 26564469] Advances in the Association between Apolipoprotein(a)Gene Polymorphisms and Coronary Heart Disease
| ClinVar | |
|---|---|
| Risk | Rs10455872(G;G) |
| Alt | Rs10455872(G;G) |
| Reference | Rs10455872(A;A) |
| Significance | Drug-response |
| Disease | HMG CoA reductase inhibitors response - Efficacy |
| Variation | info |
| Gene | LPA |
| CLNDBN | HMG CoA reductase inhibitors response - Efficacy |
| Reversed | 0 |
| HGVS | NC_000006.11:g.161010118A>G |
| CLNSRC | PharmGKB Clinical Annotation |
| CLNACC | RCV000211156.1, |
[PMID 27831500] The LPA Gene, Ethnicity, and Cardiovascular Events.
[PMID 28566218] Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
[PMID 29703846] LPA Variants are Associated with Residual Cardiovascular Risk in Patients Receiving Statins.
[PMID 30594920] Investigation of LPA sequence variants rs6415084, rs3798220 with conventional coronary artery disease in Iranian CAD patients.
[PMID 30759150] Using topic modeling via non-negative matrix factorization to identify relationships between genetic variants and disease phenotypes: A case study of Lipoprotein(a) (LPA).
[PMID 32152647] Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.
[PMID 32220223] Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification.
[PMID 32343731] A genome-wide analysis of DNA methylation identifies a novel association signal for Lp(a) concentrations in the LPA promoter.
